VKH
XLRN

Virtu KCG Holdings’s Acceleron Pharma XLRN Stock Holding History

Virtu KCG Holdings’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,165
Closed -$387K – 3961
2016
Q4 		$387K Buy
15,165
+7,509
+98% +$238K 0.01% 1807
2016
Q3 		$277K Buy
+7,656
New +$254K 0.01% 2003

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Virtu KCG Holdings's XLRN Position: Q1 2017 in Review

Virtu KCG Holdings sold out of Acceleron Pharma (XLRN) in Q1 2017, closing a stake of 15,165 shares — an estimated $387K sold.

Virtu KCG Holdings first reported a position in XLRN in Q3 2016 and held it in 2 quarters. The position peaked at $387K in Q4 2016. 136 funds tracked by Wall St. Rank hold XLRN as of Q1 2017.

  • Virtu KCG Holdings reported no remaining Acceleron Pharma position as of Q1 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 15,165 Acceleron Pharma shares in Q1 2017, an estimated $387K.
  • Virtu KCG Holdings first reported a position in Acceleron Pharma in Q3 2016 and held it in 2 quarters.
  • Virtu KCG Holdings's Acceleron Pharma position peaked at $387K in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2017.

Based on Virtu KCG Holdings's 13F filing for Q1 2017, filed 12 May 2017.